Improved Recognition of Lung Function Decline As Signal of Cystic Fibrosis Pulmonary Exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory Quality Improvement Initiative

Overview

Journal BMJ Open Qual

Publisher BMJ Publishing Group

Specialty Health Services

Date 2023 Dec 28

PMID 38154821

Authors

Rhonda List

George Solomon

Stacy Bichl

Bethany Jablonski Horton

Shiyi Shen

Bean Corcoran

Hossein Sadeghi

Maria T Britto

Clement Ren

Dana Albon

Affiliations

Soon will be listed here.

Abstract

Introduction: Cystic fibrosis (CF) is a systemic autosomal recessive condition characterised by progressive lung disease. CF pulmonary exacerbations (PEx) are episodes of worsening respiratory status, and frequent PEx are a risk factor for accelerated lung function decline, yet many people with CF (PwCF) go untreated at the time of decline. The goal of this quality improvement (QI) initiative was to improve recognition, treatment and follow-up of PEx in PwCF.

Methods: Using the Model for Improvement, the Cystic Fibrosis Learning Network (CFLN) initiated a QI innovation laboratory (iLab) with a global aim to decrease the rate of lung function decline in PwCF. The iLab standardised definitions for signals of PEx using a threshold for decline in forced expiratory volume in one second (FEV) and/or changes in symptoms. The FEV decline signal was termed FIES (FEV-indicated exacerbation signal). Processes for screening and recognition of FIES and/or symptom changes, a treatment algorithm and follow-up in the presence of a signal were tested concurrently in multiple settings.

Specific Aims: The specific aim is to increase the per cent of PwCF assessed for a PEx signal at ambulatory encounters and to increase the per cent of recommendations to follow-up within 6 weeks for PwCF experiencing a PEx signal.

Results: FIES recognition increased from 18.6% to 73.4% across all teams during the iLab, and every team showed an improvement. Of PwCF assessed, 15.8% experienced an FIES event (>10% decline in FEV per cent predicted (FEVpp)). Follow-up within 6 weeks was recommended for an average of 70.5% of those assessed for FIES and had an FEVpp decline greater than 5%.

Conclusion: The CFLN iLab successfully defined and implemented a process to recognise and follow-up PEx signals. This process has the potential to be spread to the larger CF community. Further studies are needed to assess the impact of these processes on PwCF outcomes.

Citing Articles

Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness.

Colegate S, Palipana A, Gecili E, Szczesniak R, Brokamp C J Clin Transl Sci. 2024; 8(1):e94.

PMID: 39220818 PMC: 11362628. DOI: 10.1017/cts.2024.532.

Interventions to improve system-level coproduction in the Cystic Fibrosis Learning Network.

Gamel B, Albon D, Bandla S, Davison D, Flath J, Sabadosa K BMJ Open Qual. 2024; 13(3).

PMID: 39067867 PMC: 11287073. DOI: 10.1136/bmjoq-2024-002860.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Sanders D, Bittner R, Rosenfeld M, Hoffman L, Redding G, Goss C . Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182(5):627-32. PMC: 5450763. DOI: 10.1164/rccm.200909-1421OC. View

Kraynack N, David Gothard M, Falletta L, McBride J . Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol. 2011; 46(9):870-81. DOI: 10.1002/ppul.21442. View

Ong T, Van Citters A, Dowd C, Fullmer J, List R, Pai S . Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros. 2021; 20 Suppl 3:57-63. DOI: 10.1016/j.jcf.2021.08.035. View

Albon D, Thomas L, Hoberg L, Stamper S, Somerville L, Varghese P . Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting. BMJ Open Qual. 2022; 11(2. PMC: 9121114. DOI: 10.1136/bmjoq-2022-001844. View

Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S . Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151(2):134-9, 139.e1. DOI: 10.1016/j.jpeds.2007.03.006. View

Liou T, Adler F, FitzSimmons S, Cahill B, Hibbs J, Marshall B . Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153(4):345-52. PMC: 2198936. DOI: 10.1093/aje/153.4.345. View

Goss C, Edwards T, Ramsey B, Aitken M, Patrick D . Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros. 2009; 8(4):245-52. DOI: 10.1016/j.jcf.2009.04.003. View

Schechter M, Schmidt H, Williams R, Norton R, Taylor D, Molzhon A . Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis. J Cyst Fibros. 2018; 17(6):769-778. DOI: 10.1016/j.jcf.2018.06.003. View

10.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

11.

Morgan W, Wagener J, Yegin A, Pasta D, Millar S, Konstan M . Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr. 2013; 163(4):1152-7.e2. PMC: 4064589. DOI: 10.1016/j.jpeds.2013.05.013. View

12.

Ong T, Albon D, Amin R, Bailey J, Bandla S, Britto M . Establishing a Cystic Fibrosis Learning Network: Interventions to promote collaboration and data-driven improvement at scale. Learn Health Syst. 2023; 7(3):e10354. PMC: 10336485. DOI: 10.1002/lrh2.10354. View

13.

Gold L, Patrick D, Hansen R, Goss C, Kessler L . Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). J Cyst Fibros. 2019; 18(6):886-893. PMC: 6868291. DOI: 10.1016/j.jcf.2019.05.009. View

14.

Dwight M, Marshall B . CFTR modulators: transformative therapies for cystic fibrosis. J Manag Care Spec Pharm. 2021; 27(2):281-284. PMC: 10391283. DOI: 10.18553/jmcp.2021.27.2.281. View

15.

Sanders D, Wu R, ONeil T, Elbert A, Petren K, Jain R . Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis. Ann Am Thorac Soc. 2022; 19(10):1697-1703. PMC: 9528741. DOI: 10.1513/AnnalsATS.202105-532OC. View

16.

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

17.

Wagener J, Williams M, Millar S, Morgan W, Pasta D, Konstan M . Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. J Cyst Fibros. 2018; 17(4):496-502. DOI: 10.1016/j.jcf.2018.02.003. View

18.

Collaco J, Albon D, Ostrenga J, Flume P, Schechter M, Cromwell E . Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States. J Cyst Fibros. 2022; 22(3):456-463. DOI: 10.1016/j.jcf.2022.12.004. View

19.

Albon D, Van Citters A, Ong T, Dieni O, Dowd C, Willis A . Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors. J Cyst Fibros. 2021; 20 Suppl 3:49-54. PMC: 8683127. DOI: 10.1016/j.jcf.2021.09.006. View

20.

Sanders D, Hoffman L, Emerson J, Gibson R, Rosenfeld M, Redding G . Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010; 45(2):127-34. DOI: 10.1002/ppul.21117. View